+

WO1995001170A3 - Utilisation des derives de phenethanolamine dans le traitement des troubles gastro-intestinaux - Google Patents

Utilisation des derives de phenethanolamine dans le traitement des troubles gastro-intestinaux Download PDF

Info

Publication number
WO1995001170A3
WO1995001170A3 PCT/EP1994/002106 EP9402106W WO9501170A3 WO 1995001170 A3 WO1995001170 A3 WO 1995001170A3 EP 9402106 W EP9402106 W EP 9402106W WO 9501170 A3 WO9501170 A3 WO 9501170A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
gastrointestinal disorders
phenethanolamine derivatives
hydrogen
alkyl
Prior art date
Application number
PCT/EP1994/002106
Other languages
English (en)
Other versions
WO1995001170A2 (fr
Inventor
Richard Storer
Michael Walter Foxton
Charles David Hartley
Richard Howard Green
Stuart Travers
Original Assignee
Glaxo Group Ltd
Richard Storer
Michael Walter Foxton
Charles David Hartley
Richard Howard Green
Stuart Travers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Richard Storer, Michael Walter Foxton, Charles David Hartley, Richard Howard Green, Stuart Travers filed Critical Glaxo Group Ltd
Priority to EP94923697A priority Critical patent/EP0706386A1/fr
Priority to JP7503267A priority patent/JPH08512038A/ja
Priority to AU73840/94A priority patent/AU7384094A/en
Publication of WO1995001170A2 publication Critical patent/WO1995001170A2/fr
Publication of WO1995001170A3 publication Critical patent/WO1995001170A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés de formule (I) dans laquelle: R0 est hydrogène, méthyle ou hydroxyméthyle; R1 est un alcoyle substitué; R2 et R3 sont chacun un groupe hydrogène, halogène, hydroxy, alcoxy, carboxy, alcoxycarbonyle, alcoyle, nitro, haloalkyle, ou un alcoyle substitué; X est oxygène ou soufre, et Ar est soit un phényle substitué, soit un naphtyle substitué. L'invention concerne également les sels pharmaceutiquement acceptables de ces composés servant dans le traitement des troubles gastro-intestinaux.
PCT/EP1994/002106 1993-07-01 1994-06-29 Utilisation des derives de phenethanolamine dans le traitement des troubles gastro-intestinaux WO1995001170A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP94923697A EP0706386A1 (fr) 1993-07-01 1994-06-29 Utilisation des derives de phenethanolamine dans le traitement des troubles gastro-intestinaux
JP7503267A JPH08512038A (ja) 1993-07-01 1994-06-29 胃腸障害の治療に関するフェネタノールアミン誘導体の用途
AU73840/94A AU7384094A (en) 1993-07-01 1994-06-29 Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939313574A GB9313574D0 (en) 1993-07-01 1993-07-01 Medicaments
GB9313574.7 1993-07-01

Publications (2)

Publication Number Publication Date
WO1995001170A2 WO1995001170A2 (fr) 1995-01-12
WO1995001170A3 true WO1995001170A3 (fr) 2002-02-14

Family

ID=10738090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/002106 WO1995001170A2 (fr) 1993-07-01 1994-06-29 Utilisation des derives de phenethanolamine dans le traitement des troubles gastro-intestinaux

Country Status (5)

Country Link
EP (1) EP0706386A1 (fr)
JP (1) JPH08512038A (fr)
AU (1) AU7384094A (fr)
GB (1) GB9313574D0 (fr)
WO (1) WO1995001170A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US5808080A (en) 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
DE69711519T2 (de) 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
GB9706707D0 (en) * 1997-04-02 1997-05-21 Glaxo Group Ltd Chemical compounds
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60220887T2 (de) 2001-03-08 2008-02-28 Glaxo Group Ltd., Greenford Agonisten von beta-adrenorezeptoren
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
EP2042168B1 (fr) 2001-09-14 2013-10-23 Glaxo Group Limited Formulation d'inhalation contenant des dérivés phénéthanolamines pour le traitement des maladies des voies respiratoires
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0473285A1 (fr) * 1990-07-30 1992-03-04 Imperial Chemical Industries Plc Utilisation d'acide acétique et 2-(phénoxypropanolamino)éthoxyphénoxy et ses dérivés pour l'inhibition de la motilité gastro-intestinale
EP0516349A2 (fr) * 1991-05-28 1992-12-02 Zeneca Limited Dérivés de 2-hydroxy-2-phényléthylamine comme agonistes des bêta-3-adrénoceptors
EP0543662A2 (fr) * 1991-11-20 1993-05-26 Sankyo Company Limited Dérivés d'aminoalcohol aromatique avec propriétés antidiabétiques et antiobésité, leur préparation et utilisation thérapeutique
EP0556880A2 (fr) * 1992-01-22 1993-08-25 Glaxo Group Limited L'utilisation médicale des agonistes de bêta adrénoceptor atypique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0473285A1 (fr) * 1990-07-30 1992-03-04 Imperial Chemical Industries Plc Utilisation d'acide acétique et 2-(phénoxypropanolamino)éthoxyphénoxy et ses dérivés pour l'inhibition de la motilité gastro-intestinale
EP0516349A2 (fr) * 1991-05-28 1992-12-02 Zeneca Limited Dérivés de 2-hydroxy-2-phényléthylamine comme agonistes des bêta-3-adrénoceptors
EP0543662A2 (fr) * 1991-11-20 1993-05-26 Sankyo Company Limited Dérivés d'aminoalcohol aromatique avec propriétés antidiabétiques et antiobésité, leur préparation et utilisation thérapeutique
EP0556880A2 (fr) * 1992-01-22 1993-08-25 Glaxo Group Limited L'utilisation médicale des agonistes de bêta adrénoceptor atypique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
W.J.DUNN III ET AL.: "Structure-Activity Study of beta-Adrenergic Agents Using the SIMCA Method of Pattern Recognition", J.MED.CHEM., vol. 21, no. 9, 1978, pages 922 - 930 *

Also Published As

Publication number Publication date
EP0706386A1 (fr) 1996-04-17
JPH08512038A (ja) 1996-12-17
GB9313574D0 (en) 1993-08-18
WO1995001170A2 (fr) 1995-01-12
AU7384094A (en) 1995-01-24

Similar Documents

Publication Publication Date Title
AU7578894A (en) Methods for inhibiting smooth muscle cell proliferation and restinosis
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
ES2187473T3 (es) Triarylimidazoles.
WO1995001170A3 (fr) Utilisation des derives de phenethanolamine dans le traitement des troubles gastro-intestinaux
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
ATE502932T1 (de) Makrocyclische analoga und verfahren zu ihrer verwendung und herstellung
HU9600834D0 (en) Quinazoline derivatives
BG106586A (en) Pyrazolopyramidines as therapeutic agents
ES2157957T3 (es) Procedimientos para inhibir la endometriosis.
AU2001272666A1 (en) 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
WO1999024022A3 (fr) Derives d'isoquinoline utilises pour traiter les troubles du snc
SE9701304D0 (sv) Compounds
AU635779B2 (en) 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy
WO1999012933A3 (fr) Derives de pyrrolopyrrolone en tant qu'inhibiteurs de neutrophile elastase
CA2412596A1 (fr) Inhibiteurs de phosphodiesterase specifique de gmp cyclique
SE9803773D0 (sv) Compounds
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
EP1121932A4 (fr) Medicaments pour maladies oculaires
DE69430074D1 (de) Analgetische 4-arylisoindolen
AU580162B2 (en) 1,3-oxathiane derivatives
EP0204003A4 (fr) Derives de 2-(1-piperazinyle)-4-substitue phenylquinoline, procede de preparation et composition medicinale les contenant.
EP0785193A4 (fr) Derive d'arylthiadiazole et agent antiviral le contenant
TW429147B (en) Pharmaceutical composition for the treatment of CNS disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994923697

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 564279

Date of ref document: 19960314

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1994923697

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWR Wipo information: refused in national office

Ref document number: 1994923697

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994923697

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载